Question 1

How will the 2026 ACA silver plans price GLP‑1 drugs after CMS rule?

Accepted Answer

Beginning in 2026, ACA marketplace silver plans are moving GLP‑1 agonists like semaglutide and tirzepatide into higher‑cost, nonpreferred brand tiers with coinsurance around 40–50% after deductibles. The CMS rule stops manufacturer copay coupons from counting toward out‑of‑pocket limits, raising member costs and prompting insurers to revise silver plan premiums.

Question 2

How do ACA marketplace formularies decide preferred and specialty drug tiers?

Accepted Answer

ACA marketplace plans group drugs into tiers—preferred generics, non‑preferred brands, and specialty drugs—based on negotiated pricing and cost controls. Each tier carries different cost‑sharing rules, with lower tiers encouraging cheaper generics and higher tiers requiring greater patient payments or prior authorization.

Question 3

How does the ACA benchmark plan influence prescription drug coverage and networks?

Accepted Answer

The ACA Marketplace benchmark plan—the second‑lowest‑cost Silver option—sets the reference premium that determines subsidy amounts, indirectly shaping drug coverage and network access. Because each insurer designs its own formulary, small benchmark price shifts can redirect enrollment toward plans with varying medication lists, prior‑authorization rules, and pharmacy networks.

Question 4

How do ACA marketplace plans handle non-formulary drug exception requests?

Accepted Answer

ACA marketplace plans usually start with the formulary, then require a non-formulary exception or medical necessity review if the prescribed drug is not listed. The plan typically checks whether covered alternatives are appropriate first, and approval often depends on documentation showing intolerance, contraindications, lack of effectiveness, or the need to maintain treatment stability.

Question 5

How do ACA marketplace plans cover drugs not on formulary?

Accepted Answer

ACA marketplace plans may still cover an off-formulary drug, but usually only through a formulary exception request backed by medical justification from the prescriber. Even then, the plan can still require prior authorization or step therapy, and a denial can usually be appealed through the plan’s formal review process.

Question 6

How are PBMs changing formulary rebates for Eylea biosimilars in 2026?

Accepted Answer

By mid‑2026, PBMs are overhauling rebate and formulary structures for aflibercept biosimilars after CMS finalized interchangeability guidance and faster ASP reporting. These updates compress rebate margins and push plans toward net‑effective‑price models that reward biosimilar uptake, altering rebate guarantees and tier placements across Medicare and commercial formularies.

Question 7

How will UnitedHealthcare’s 2026 formulary treat Humira and its biosimilars?

Accepted Answer

UnitedHealthcare’s 2026 formulary strategy places at least one interchangeable Humira biosimilar, such as Amjevita or Hadlima, on Tier 2 as preferred drugs, while Humira itself moves to Tier 3 or non‑formulary status. This shift follows CMS guidance promoting interchangeable biosimilars and is expected to lower member costs by about 20% compared to Humira’s net price.

Question 8

How are 2026 Medicare Advantage plans prioritizing Amjevita and Cyltezo after CMS billing updates?

Accepted Answer

CMS’s 2026 billing guidance standardized coding for interchangeable adalimumab biosimilars, prompting Medicare Advantage plans to favor Amjevita and Cyltezo in step‑therapy sequences. Amjevita’s early market entry and Cyltezo’s interchangeability status led PBMs to place them on preferred specialty tiers ahead of Humira and other non‑interchangeable biosimilars.

Question 9

How will 2026 ACA Marketplace plans tier Stelara biosimilars after FDA approval?

Accepted Answer

For 2026 ACA Marketplace plans, insurers are shifting interchangeable Stelara biosimilars into preferred specialty tiers with lower coinsurance, typically 25–35%, compared to Stelara’s 35–50% in non-preferred tiers. The FDA’s interchangeability approval allows substitution at the pharmacy, driving payers to promote biosimilar use while controlling premium growth.

Question 10

How will Stelara biosimilars affect 2026 employer drug plan coverage?

Accepted Answer

In 2026, employer prescription plans are being reshaped by the arrival of ustekinumab biosimilars for Stelara, now granted FDA interchangeability under new CMS rules. These biosimilars are driving formulary changes, with many employer plans shifting them to lower specialty tiers and using IRA-aligned Medicare pricing to reduce overall specialty drug costs.

Question 11

How do step therapy and interchangeability rules affect biosimilar substitution?

Accepted Answer

Step therapy requires patients to try a plan’s preferred biosimilar before accessing the reference biologic, while interchangeability rules govern if a pharmacist can automatically substitute a biosimilar. Most biosimilars lack FDA interchangeability status, so substitution typically needs prescriber approval under state and plan policies.

Question 12

How do state Medicaid programs decide on mandatory biosimilar substitution?

Accepted Answer

State Medicaid programs base mandatory biosimilar substitution decisions on FDA definitions of interchangeability and state-specific pharmacy laws. Agencies assess whether pharmacists can substitute without prescriber approval, then weigh clinical data, interchangeability status, and net cost to assign preferred drug list placement.

Question 13

How do commercial health plans set step therapy rules for interchangeable biosimilars?

Accepted Answer

Commercial health plans individually decide how to structure step therapy sequences for interchangeable biosimilars versus reference biologics, since no binding regulation mandates a uniform approach. Some plans start with the biosimilar as the first step, while others keep the reference biologic first, often influenced by rebates or utilization patterns.

Question 14

Does biosimilar interchangeability affect formulary placement and pharmacy coverage decisions?

Accepted Answer

Interchangeability and formulary placement are related but separate. Interchangeability affects whether a pharmacist may substitute a biosimilar under applicable rules, while formulary placement determines which product a plan prefers, covers, or places on a lower tier. A biosimilar can be covered or preferred even if it is not interchangeable.

Question 15

Can a health plan require prior authorization for a biosimilar?

Accepted Answer

Yes. A health plan can require prior authorization for a reference biologic, a biosimilar, or both to confirm formulary rules, step therapy, site-of-care, or other benefit terms. That payment decision is separate from whether a pharmacist may legally substitute the biosimilar without a new prescription.

Question 16

What triggers mid-year formulary tier changes in employer health plans?

Accepted Answer

Mid-year formulary tier changes in employer health plans are typically triggered by factors such as manufacturer price adjustments, new generic launches, safety advisories, or rebate and cost shifts. Pharmacy benefit managers use these updates to keep formularies financially balanced and ensure coverage reflects current market and regulatory conditions.

Question 17

How do self‑funded employers decide which specialty drugs to carve out?

Accepted Answer

Self‑funded employers analyze claims data to identify high‑cost specialty drugs, often biologics or infused therapies, and assess alternatives like direct purchasing through specialty pharmacies or manufacturer programs. They weigh cost transparency, clinical interchangeability, and network rules to manage these drugs outside PBM formularies and reduce administrative and rebate‑related costs.

Question 18

How do employer health plans handle mid-year formulary tier changes?

Accepted Answer

Employer-sponsored health plans sometimes adjust their prescription drug formularies mid-year in response to pricing shifts, new generics, or safety updates. When they do, they must follow notice rules requiring prior communication to employees, explaining timing and impact to prevent sudden cost or treatment disruptions.

Question 19

How do self-funded employer plans handle formulary exception requests for specialty drugs?

Accepted Answer

Self-funded employer plans review formulary exception requests through their pharmacy benefit manager (PBM), which evaluates medical necessity, prior treatment history, and documentation. Employers can set their own criteria and involvement level, balancing cost management with clinical evidence before approving or denying coverage for non-formulary specialty drugs.

Question 20

How do employer-sponsored health plans handle formulary exception requests?

Accepted Answer

Employer-sponsored health plans use a structured process to review formulary exception requests for non-covered or higher-tier drugs. Physicians submit clinical justification showing why formulary alternatives failed or caused adverse reactions. The insurer or PBM conducts a clinical review under employer oversight, ensuring consistent, evidence-based determinations aligned with ERISA duties.

Question 21

How do employer plan SBCs show prescription drug cost-sharing rules?

Accepted Answer

Employer-plan SBCs summarize whether prescription drugs are subject to a deductible, use copayments or coinsurance, and vary by tiers such as generic, preferred, nonpreferred, or specialty. They show the broad cost-sharing structure, but readers still need the formulary and pharmacy benefit rules to confirm covered drugs, exceptions, and utilization management details.

Question 22

How do employer plans handle non-formulary exceptions when alternatives are inappropriate?

Accepted Answer

Employer-sponsored plans usually review non-formulary exception requests through the carrier or PBM when covered formulary drugs are medically inappropriate for a specific patient. The prescriber must document why alternatives are ineffective, not tolerated, contraindicated, or otherwise unsuitable, and denials can typically be appealed.

Question 23

How do PBM rebates affect formulary tiers and drug cost sharing?

Accepted Answer

PBM rebates can influence whether a drug gets preferred formulary placement, lands on a lower tier, or faces fewer controls like prior authorization or step therapy in employer plans. But preferred status does not always lower a member’s out-of-pocket costs, because deductibles, coinsurance, and plan design still determine what the member pays.

Question 24

How are Medicare Part D formularies changing Eliquis and Xarelto tiers in 2026?

Accepted Answer

Starting January 2026, CMS’s first negotiated price cuts under the Inflation Reduction Act lowered Eliquis and Xarelto list prices by about 25–30%, prompting Part D plans to move them to lower formulary tiers. Many major sponsors like SilverScript and Humana now list both drugs as Tier 2 preferred brands, reducing coinsurance and overall patient out-of-pocket costs.

Question 25

How does a Medicare Part D formulary exception work when my drug isn’t covered?

Accepted Answer

A Medicare Part D formulary exception lets a plan cover a drug not on its official list when medical need is shown. The prescriber submits documentation explaining why listed alternatives don’t work, and the plan must decide within required timeframes. Once approved, the drug is treated as covered—often at a certain tier—for the rest of the plan year.

Figuring out drug coverage shouldn't be this hard

What's going on?

What type of insurance do you have?

What medication are you looking up?